#chemocentryx

📰 அரிய தன்னுடல் தாக்க நோய்க்கு சிகிச்சையளிக்கப் பயன்படுத்தப்படும் ChemoCentryx இன் அவகோபன் ஒப்புதல் பெறுகிறது | உலக செய்திகள்

ChemoCentryx Inc வெள்ளிக்கிழமை அமெரிக்க சுகாதார நிறுவனம் ஒரு அரிய, அபாயகரமான தன்னுடல் தாக்க நோய்க்கு சிகிச்சையளிக்க அதன் முன்னணி மருந்தை அங்கீகரித்து, உயிர் மருந்தியல் நிறுவனத்தின் பங்குகளை 70%க்கும் அதிகமாக அனுப்பியது. அடுத்த சில வாரங்களில் டாவ்னியோஸ் என்ற பிராண்ட் பெயரில் கிடைக்கும் அவகோபன் என்ற மருந்து, ஒரு நோயாளிக்கு வருடத்திற்கு $ 150,000 முதல் $ 200,000 வரை மொத்த விலையாக இருக்கும் என்று…

ChemoCentryx (CCXI) Q4 2017 Earnings Conference Call Transcript

Image source: The Motley Fool. ChemoCentryx (NASDAQ: CCXI) Q4 2017 Earnings Conference Call March 9, 2018 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Ladies and gentlemen, please stand by your conference call will begin momentarily. Again thank you for your patience an… Latest Articles in

ChemoCentryx, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'ChemoCentryx, Inc. - Product Pipeline Review - 2016', provides an overview of the ChemoCentryx, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ChemoCentryx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

To Access Browse Full Research Report @: http://www.radiantinsights.com/research/chemocentryx-inc-product-pipeline-review-2016

Scope

The report provides a snapshot of the pipeline therapeutic landscape of ChemoCentryx, Inc.

The report provides overview of ChemoCentryx, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses ChemoCentryx, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features ChemoCentryx, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate ChemoCentryx, Inc.'s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for ChemoCentryx, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding ChemoCentryx, Inc.'s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To AccessRequest A Sample Copy Of This Report at: http://www.radiantinsights.com/research/chemocentryx-inc-product-pipeline-review-2016/request-sample

About Radiant Insights: Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

ChemoCentryx Inc (NASDAQ:CCXI) just put out initial data from its early stage pancreatic cancer trial, and the company is down close to 15% on the numbers. It looks like there may be further losses heading into the close of the US session ahead of Labor Day. Here’s what’s important, and what we can expect when the markets come back in to delayed play next week.

Let’s take a look at the drug first.

It’s a pancreatic cancer target, called CCX872, and its primary function is the inhibition of a receptor called CCR2. The science behind this one isn’t too complicated, and for those familiar with the way immuno-oncology works, it will be a well versed concept. CCR2 is one of the receptors responsible for hiding the tumorous cell from the T cells of the immune system. They are expressed on the outside of cancer cells, and they mimic the receptors of a healthy cell. When the T cells come along, the reach out to identify the cell type. The cancer cell reaches back with its CCR2, and the T cell links up, check it out, wrongly recognizes it as a host cell, and moves along.

CCR2 inhibition means that the receptor is essentially blocked, so when the T cell reaches out to the cancerous cell there is no link that it can form that signals that the cancer cell is a harmless host cell. No link sets off alarm bells for the T cell, and the T cell sends a signal that rounds up the rest of the immune system for attack.

That’s the theory, at least.

The data wasn’t that great – well, what data there is. The numbers showed an ORR of 37% in a pre specified evaluable population (one that had had at least one baseline scan), reducing to 30% in the entire population (with and without baseline scam n=50).

On it’s own, this might not be bad data, but the study is looking at a combination of CCX872 and standard of care combination referred to as FOLFIRINOX. FOLFIRINOX is an acronym of four chemotherapy agents – 5-fluorouracil, leucovorin, irinotecan and oxaliplatin.

It’s not all that bad, however. The study is primarily a safety study, and according to the data there is no discernible difference between the safety profile normally associated with FOLFIRINOX treatment and that which displayed as a result of this study – so far.

We expect that this will level out once markets resume next week. Things don’t look great right now, but they don’t look terrible, and there’s plenty of room for an efficacy showing in a wider patient population moving forward.

PFS data is set for the end of 2016, and that’s going to be an important release. We’ll keep an eye on things heading forward and update as appropriate.